Technical analysis of Ovid Therapeutics Inc. (OVID): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infa...
Price Performance
| 1 month | -5.63% |
| 3 months | +18.06% |
| Year-to-date | +64.42% |
| 1 year | +131.03% |
| 3 years | -29.29% |
| 5 years | -20.47% |
52-Week Range
| 52-week High | $3.11 |
| 52-week Low | $1.12 |
| Avg Volume (90d) | 2.1M |
Technical Indicators
| SMA 50 | $2.62 |
| SMA 200 | $2.24 |
| Beta | -0.03 |
| 30-day Volatility (annualised) | 44.0% |
| Price vs SMA 50 | +2.4% |
| Price vs SMA 200 | +19.6% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $1.39 | |
| 2025-11 | $1.78 | +28.1% |
| 2025-12 | $1.63 | -8.4% |
| 2026-01 | $1.56 | -4.3% |
| 2026-02 | $1.63 | +4.5% |
| 2026-03 | $2.22 | +36.2% |
| 2026-04 | $2.77 | +24.8% |
| 2026-05 | $2.73 | -1.4% |
| 2026-06 | $2.69 | -1.5% |
| 2026-07 | $2.22 | -17.5% |
| 2026-08 | $2.67 | +20.3% |
| 2026-09 | $2.68 | +0.4% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $2.68 |
| Market Cap | $500M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.96 |
| EV / EBITDA | -14.12 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.06 |
| Current Ratio | 12.39 |